Bracanat 150mg Tablet (Olaparib)

Bracanat 150mg Tablet is a prescription anticancer medicine containing Olaparib 150mg. It belongs to a group of targeted cancer medicines known as PARP inhibitors. Patients and caregivers searching for Bracanat 150mg uses, Bracanat 150mg composition, or what Bracanat 150mg Tablet is used for should know that olaparib is used in carefully selected cancers where defective DNA-repair pathways make tumour cells particularly sensitive to PARP inhibition.

PARP enzymes help cells repair certain types of DNA damage. By inhibiting PARP, Olaparib 150mg Tablet can prevent susceptible cancer cells from repairing damaged DNA effectively, which may ultimately lead to cancer-cell death. Depending on the approved disease setting and biomarker profile, olaparib may be used in selected patients with ovarian cancer, breast cancer, pancreatic cancer and prostate cancer.

Testing for BRCA1, BRCA2, homologous-recombination repair (HRR) alterations or homologous-recombination deficiency (HRD) may be required before treatment. This makes Bracanat 150mg for BRCA-mutated cancer an important biomarker-directed treatment rather than a general cancer medicine.
Olaparib also uses a biological principle known as synthetic lethality. Tumour cells that already have defective homologous-recombination DNA repair, including certain BRCA1/BRCA2-mutated cancers, can become highly dependent on PARP-mediated repair. Blocking PARP may therefore make these cancer cells particularly vulnerable.

Bracanat 150mg Tablet is manufactured/marketed by Natco Pharma Ltd. It is available in India as a prescription medicine and should only be started and monitored by an oncologist.

Patients searching for Bracanat 150mg price, Bracanat 150mg availability, Bracanat 150mg where to buy or Bracanat 150mg buy online should verify the current prescription, stock and pack before purchase. 

Quick Product Facts

How Bracanat 150mg Tablet Works

Patients often search how Bracanat 150mg works or Olaparib mechanism of action.

Olaparib inhibits PARP1, PARP2 and PARP3, enzymes involved in repairing single-strand DNA breaks. When these PARP enzymes are blocked, unrepaired DNA damage may be converted into more serious double-strand DNA breaks during cell division. Healthy cells with functioning homologous-recombination repair pathways may be able to repair much of this damage.

However, tumour cells carrying abnormalities in BRCA1, BRCA2 or other HRR genes may already have impaired double-strand DNA repair. The combination of existing DNA-repair deficiency plus PARP inhibition can cause an accumulation of DNA damage that susceptible cancer cells cannot survive.

This mechanism is called synthetic lethality and explains why PARP inhibitors such as olaparib can be particularly effective in selected BRCA-mutated or HRR-deficient cancers.

Clinical Evidence for Olaparib

The following pivotal studies support olaparib in major treatment settings. Trial results do not guarantee an individual patient's response, and eligibility must match the current approved indication.

These trials provide the major evidence base behind searches such as Olaparib effectiveness, Bracanat 150mg benefits, PARP inhibitor treatment, and Olaparib for BRCA-mutated cancer.​

Bracanat 150mg Dosage and How To Take It

Patients frequently search for Bracanat 150mg dosage, Bracanat 150mg dose and how to take Bracanat 150mg Tablet.

For olaparib tablets, the commonly labelled adult dose is 300 mg orally twice daily. This means 2 × Bracanat 150mg tablets per dose, taken twice daily. The doses are generally taken approximately 12 hours apart.

Typical Olaparib Dose Information

These are molecule-level prescribing-information doses. The oncologist must determine the appropriate Bracanat 150mg dosage for each patient.

Administration Guidance

Take Bracanat 150mg Tablet exactly as prescribed. Olaparib tablets can generally be taken with or without food. Swallow the tablets whole with water. Do not crush, chew or split the tablets unless the specific product information permits this. Take doses at approximately the same times each day. Do not change the dose or stop olaparib treatment without consulting your oncologist.

Avoid grapefruit, grapefruit juice, Seville oranges, and products containing these fruits because they can interfere with CYP3A metabolism and may increase olaparib exposure.

Critical Safety Warning

IMPORTANT SAFETY WARNING: Olaparib can cause serious bone-marrow toxicity. Rare cases of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have occurred and some cases have been fatal. Persistent cytopenias should therefore be investigated promptly. Pneumonitis, venous thromboembolism and hepatotoxicity have also been reported during olaparib treatment.

Patients should seek medical attention for symptoms such as:

·        Persistent fever

·        Recurrent infections

·        Unusual bruising or bleeding

·        Severe weakness

·        Persistent shortness of breath

·        New or worsening cough

·        Chest pain

·        Leg swelling

·        Symptoms suggestive of liver injury

Bracanat 150mg Fact Box

Bracanat 150mg Drug Interactions

Patients searching Bracanat drug interactions or Olaparib interactions should be aware that CYP3A interactions are particularly important.

Patients should tell their oncologist about all prescription medicines, OTC medicines, herbal medicines, vitamins and nutritional supplements before starting Bracanat 150mg.

Bracanat ​150mg Uses and Indications

Bracanat 150mg uses depend on the type of cancer, disease stage, previous treatment and results of molecular or genetic testing. The active molecule olaparib has demonstrated benefit in several biomarker-selected cancer settings.

Ovarian, Fallopian-Tube and Primary Peritoneal Cancer

Olaparib is used in selected patients with advanced or recurrent ovarian cancer, fallopian-tube cancer and primary peritoneal cancer, particularly in maintenance-treatment settings after response to platinum-based chemotherapy. In some settings, eligibility depends on BRCA1/BRCA2 mutation or HRD status. One of the major studies supporting this indication is the SOLO-1 trial, which established substantial benefit from first-line maintenance olaparib in appropriately selected patients with BRCA-mutated advanced ovarian cancer.

HER2-Negative Breast Cancer

Olaparib for breast cancer may be considered for selected patients with HER2-negative breast cancer associated with germline BRCA mutations. HER2-negative disease can include both hormone-receptor-positive breast cancer and triple-negative breast cancer. Eligibility for olaparib depends on the specific disease stage, prior treatment and BRCA mutation status. The OlympiAD trial provided pivotal evidence supporting olaparib in germline BRCA-mutated, HER2-negative metastatic breast cancer.

Pancreatic Cancer

Bracanat 150mg for pancreatic cancer may be relevant in selected patients with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed after an appropriate course of first-line platinum-based chemotherapy. The POLO trial established the role of maintenance olaparib in this highly selected population.

Prostate Cancer

Olaparib for prostate cancer is used in selected patients with metastatic castration-resistant prostate cancer (mCRPC) carrying qualifying homologous-recombination repair alterations. The PROfound trial provided important evidence for olaparib in men with selected HRR-altered metastatic castration-resistant prostate cancer. Bracanat should not be prescribed merely because a tumour is described as 'BRCA-like.' Appropriate validated biomarker testing and specialist oncology assessment are required.

Bracanat 150mg side effects vary according to the indication, combination regimen, treatment duration and individual patient factors.

·        Nausea

·        Vomiting

·        Fatigue or weakness

·        Anaemia

·        Neutropenia or low white-blood-cell count

·        Thrombocytopenia or low platelets

·        Diarrhoea

·        Reduced appetite

·        Headache

·        Dizziness

·        Dysgeusia or altered taste

·        Abdominal discomfort

Serious Side Effects

·        Persistent bone-marrow suppression

·        Myelodysplastic syndrome (MDS)

·        Acute myeloid leukaemia (AML)

·        Pneumonitis or interstitial lung disease

·        Venous thromboembolism in selected treatment settings

·      Hepatotoxicity or drug-induced liver injury

·     Severe anaemia, neutropenia or thrombocytopenia

Patients often search how Bracanat 150mg works or Olaparib mechanism of action.

Olaparib inhibits PARP1, PARP2 and PARP3, enzymes involved in repairing single-strand DNA breaks. When these PARP enzymes are blocked, unrepaired DNA damage may be converted into more serious double-strand DNA breaks during cell division. Healthy cells with functioning homologous-recombination repair pathways may be able to repair much of this damage.

However, tumour cells carrying abnormalities in BRCA1, BRCA2 or other HRR genes may already have impaired double-strand DNA repair. The combination of existing DNA-repair deficiency plus PARP inhibition can cause an accumulation of DNA damage that susceptible cancer cells cannot survive.

This mechanism is called synthetic lethality and explains why PARP inhibitors such as olaparib can be particularly effective in selected BRCA-mutated or HRR-deficient cancers.

Bracanat 150mg Missed Dose
If you miss a Bracanat 150mg dose, take the next dose at the regularly scheduled time. Do not take an extra dose or double the next dose. If vomiting occurs after taking Bracanat, do not automatically repeat the dose. Take the next scheduled dose at the usual time. Contact your oncology team if several doses are missed. 

Monitoring During Bracanat Treatment
Blood Tests
A complete blood count (CBC) should be checked before treatment and regularly during therapy. Current olaparib prescribing information recommends at least monthly CBC monitoring. This helps identify anaemia, neutropenia, thrombocytopenia, and persistent cytopenias that may require investigation for MDS/AML.
Kidney Function
Renal function should be assessed before treatment and periodically because olaparib exposure increases in renal impairment.
Liver Function
Liver-function testing may be required, especially where there are baseline risk factors or symptoms suggesting hepatotoxicity.
Respiratory Symptoms
New or worsening cough, breathlessness, fever or chest symptoms should be investigated because olaparib-associated pneumonitis can occur.
Thrombosis Monitoring
Symptoms such as sudden breathlessness, chest pain or unilateral leg swelling require prompt evaluation for possible venous thromboembolism.
Practical Monitoring Checklist
• Complete blood count before treatment
• CBC at least monthly or according to oncology protocol
• Renal function
• Liver-function tests as clinically indicated
• Assessment of persistent cytopenias
• Monitoring for respiratory symptoms
• Monitoring for thrombosis symptoms
• Treatment-response imaging according to the cancer type
• Adherence and drug-interaction review

1. FDA. Lynparza (olaparib) Prescribing Information, current prescribing information.

2. European Medicines Agency. Lynparza Product Information / SmPC.

3. Natco Pharma. Bracanat / Olaparib product information and oncology catalogue.

4. SOLO-1 - pivotal olaparib evidence in BRCA-mutated advanced ovarian cancer.

5. OlympiAD - pivotal olaparib evidence in germline BRCA-mutated HER2-negative metastatic breast cancer.

6. POLO - pivotal olaparib maintenance evidence in germline BRCA-mutated metastatic pancreatic cancer.

7. PROfound - pivotal olaparib evidence in HRR-altered metastatic castration-resistant prostate cancer.

Clinical evidence reviewed: SOLO-1, OlympiAD, POLO and PROfound.

Brand information reviewed: Bracanat 150mg Tablet, Natco Pharma Ltd.